Jodi L. Pawluski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jodi L. Pawluski has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Liisa Ann Margaret Galea
Graduate Program in Neuroscience, University of British Columbia, Vancouver, BC, Canada
15 shared publications Thierry D. Charlier
Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085 Rennes France
13 shared publications- Mary Gemmel
Department of Biological Sciences, Ohio University, Athens, OH, USA
9 shared publications - Timothy F. Oberlander
University of British Columbia
9 shared publications - Daniel Louis Albert Van Den Hove
Maastricht University
8 shared publications Ine Rayen
Department of Neuroscience, Maastricht University, Netherlands
8 shared publications
Latest Publications
- 20 August 2026
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 28 (1) , 64
Maternal Neuroplasticity: Understanding Brain Changes with Perinatal Depression and Anxiety in Women
Purpose of the review The transition to parenthood is a unique period of adulthood during which the brain undergoes profound and rapid changes, particularly in birthing mothers. This transition is also associated with a risk of developing mental illness, likely due to intersections among the neurobiological changes and a host of psychosocial factors including one’s history of mental illness and lack of adequate support systems for parents. Recent findings Emerging evidence indicates that perinatal depression and anxiety are associated with distinct neural alterations that overlap with the brain areas also involved in caregiving. Thus, there is a critical need to better understand the neurobiological mechanisms underlying perinatal mental illness for both maternal and child wellbeing. The goals of this review are to highlight key findings from current research on the ways in which human brain function and structure are associated with (1) perinatal depression, (2) perinatal anxiety, and (3) treatments aimed at promoting parental mental health. Summary Advances in understanding the neuroplasticity associated with perinatal depression and anxiety will inform the development of targeted interventions and treatments aimed at supporting parental wellbeing, promoting healthy parent–infant relationships, and improving peripartum brain health.
- 20 August 2026
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 28 (1) , 64
Maternal Neuroplasticity: Understanding Brain Changes with Perinatal Depression and Anxiety in Women
Purpose of the review The transition to parenthood is a unique period of adulthood during which the brain undergoes profound and rapid changes, particularly in birthing mothers. This transition is also associated with a risk of developing mental illness, likely due to intersections among the neurobiological changes and a host of psychosocial factors including one’s history of mental illness and lack of adequate support systems for parents. Recent findings Emerging evidence indicates that perinatal depression and anxiety are associated with distinct neural alterations that overlap with the brain areas also involved in caregiving. Thus, there is a critical need to better understand the neurobiological mechanisms underlying perinatal mental illness for both maternal and child wellbeing. The goals of this review are to highlight key findings from current research on the ways in which human brain function and structure are associated with (1) perinatal depression, (2) perinatal anxiety, and (3) treatments aimed at promoting parental mental health. Summary Advances in understanding the neuroplasticity associated with perinatal depression and anxiety will inform the development of targeted interventions and treatments aimed at supporting parental wellbeing, promoting healthy parent–infant relationships, and improving peripartum brain health.
- 14 May 2026
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (3) , 81
Letter to the editor: Beyond reductionism in postpartum depression treatment and toward systems-oriented maternal mental health care
Postpartum depression (PPD) is a heterogeneous mood disorder emerging within the first year after childbirth and shaped by interacting biological, psychological, and social factors. Although treatment is commonly adapted from major depressive disorder, the postpartum period represents a distinct and dynamically regulated physiological state. Rapid hormonal withdrawal, neuroendocrine recalibration, immune shifts, and adaptive neuroplastic changes occur concurrently, contributing to variable treatment response and clinical heterogeneity. Viewing PPD as a disorder of systems-level dysregulation has important implications for research and therapy. Single-target pharmacological approaches may have limited effectiveness when multiple interconnected pathways are involved. Interventions capable of modulating interacting physiological systems, including carefully evaluated multi-component and herbal therapies, warrant rigorous investigation. Future research should incorporate biological stratification, biomarker-informed trial designs, postpartum-specific models, and stringent safety evaluation. Advancing systems-oriented research frameworks may support more precise, effective, and biologically coherent therapeutic strategies for maternal mental health.
- 14 May 2026
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (3) , 81
Letter to the editor: Beyond reductionism in postpartum depression treatment and toward systems-oriented maternal mental health care
Postpartum depression (PPD) is a heterogeneous mood disorder emerging within the first year after childbirth and shaped by interacting biological, psychological, and social factors. Although treatment is commonly adapted from major depressive disorder, the postpartum period represents a distinct and dynamically regulated physiological state. Rapid hormonal withdrawal, neuroendocrine recalibration, immune shifts, and adaptive neuroplastic changes occur concurrently, contributing to variable treatment response and clinical heterogeneity. Viewing PPD as a disorder of systems-level dysregulation has important implications for research and therapy. Single-target pharmacological approaches may have limited effectiveness when multiple interconnected pathways are involved. Interventions capable of modulating interacting physiological systems, including carefully evaluated multi-component and herbal therapies, warrant rigorous investigation. Future research should incorporate biological stratification, biomarker-informed trial designs, postpartum-specific models, and stringent safety evaluation. Advancing systems-oriented research frameworks may support more precise, effective, and biologically coherent therapeutic strategies for maternal mental health.
- 4 September 2025
- Published by Springer Nature in Nature Mental Health
- Vol. 3 (11) , 1304-1310
Potential risks and benefits of prenatal selective serotonin reuptake inhibitor medications for maternal mental health and child development
- 4 September 2025
- Published by Springer Nature in Nature Mental Health
- Vol. 3 (11) , 1304-1310
Potential risks and benefits of prenatal selective serotonin reuptake inhibitor medications for maternal mental health and child development
- Open Access
- 22 July 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (12) , e70068
Reproductive experience influences the effects of Lactocaseibacillus rhamnosus HN001 on gut microbiota and hippocampal plasticity in female rats
There is increasing interest in the role of probiotics in supporting maternal well‐being throughout female reproduction. However, it remains largely unknown whether the brain of a female with reproductive experience responds differently to probiotics compared to females without reproductive experience. Reproduction involves remarkable neuroplasticity; therefore, we hypothesized that reproducing females are particularly susceptible to the effects of probiotic treatment. Groups of early pregnant or age‐matched virgin female Long–Evans rats were administered the probiotic, Lactocaseibacillus rhamnosus HN001 (HN001), in their drinking water or given untreated water for 30 days. To measure changes in gut microbiota, fecal samples were taken regularly. Brains were analyzed at the end of treatment to quantify hippocampal cells containing the neurogenesis marker doublecortin, the synaptic marker synaptophysin, and the microglial activation marker Iba1. For dams, an offspring retrieval test was performed. Main findings show that HN001 administration lowers Bacteroidota abundance in the gut regardless of reproductive experience. In HN001‐treated dams there was an increase in the number of times offspring were carried and this was negatively correlated with Bacteroidota abundance in the dam's gut. HN001‐treated dams also had more immature neurons in the hippocampus and more thick‐type microglial cells in the dorsal hippocampus compared to control dams. HN001‐treated females, regardless of reproductive experience, had lower density of synaptophysin immunoreactivity in the CA1, and more thick‐type microglia cells in the ventral hippocampus, compared to control females. These results indicate that the probiotic, HN001, alters female rat maternal behavior, plasticity in the hippocampus, and the gut microbiota abundance, with some effects being influenced by reproductive experience.
- 22 July 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (12) , e70068
Open AccessReproductive experience influences the effects of Lactocaseibacillus rhamnosus HN001 on gut microbiota and hippocampal plasticity in female rats
There is increasing interest in the role of probiotics in supporting maternal well‐being throughout female reproduction. However, it remains largely unknown whether the brain of a female with reproductive experience responds differently to probiotics compared to females without reproductive experience. Reproduction involves remarkable neuroplasticity; therefore, we hypothesized that reproducing females are particularly susceptible to the effects of probiotic treatment. Groups of early pregnant or age‐matched virgin female Long–Evans rats were administered the probiotic, Lactocaseibacillus rhamnosus HN001 (HN001), in their drinking water or given untreated water for 30 days. To measure changes in gut microbiota, fecal samples were taken regularly. Brains were analyzed at the end of treatment to quantify hippocampal cells containing the neurogenesis marker doublecortin, the synaptic marker synaptophysin, and the microglial activation marker Iba1. For dams, an offspring retrieval test was performed. Main findings show that HN001 administration lowers Bacteroidota abundance in the gut regardless of reproductive experience. In HN001‐treated dams there was an increase in the number of times offspring were carried and this was negatively correlated with Bacteroidota abundance in the dam's gut. HN001‐treated dams also had more immature neurons in the hippocampus and more thick‐type microglial cells in the dorsal hippocampus compared to control dams. HN001‐treated females, regardless of reproductive experience, had lower density of synaptophysin immunoreactivity in the CA1, and more thick‐type microglia cells in the ventral hippocampus, compared to control females. These results indicate that the probiotic, HN001, alters female rat maternal behavior, plasticity in the hippocampus, and the gut microbiota abundance, with some effects being influenced by reproductive experience.
- Open Access
- 5 December 2024
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 28 (1) , 1-3
Cognition and motherhood: a key to understanding perinatal mental health?
- 5 December 2024
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 28 (1) , 1-3
Open AccessCognition and motherhood: a key to understanding perinatal mental health?
- Open Access
- 14 July 2024
- Published by Elsevier in Seminars in Perinatology
- Vol. 48 (6) , 151951
The parental brain, perinatal mental illness, and treatment: A review of key structural and functional changes
- 14 July 2024
- Published by Elsevier in Seminars in Perinatology
- Vol. 48 (6) , 151951
Open AccessThe parental brain, perinatal mental illness, and treatment: A review of key structural and functional changes
- 25 June 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (7) , 764-772
Understanding the maternal brain in the context of the mental load of motherhood
- 25 June 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (7) , 764-772
Understanding the maternal brain in the context of the mental load of motherhood
- 19 March 2024
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 165, 107033
Maternal probiotic Lactocaseibacillus rhamnosus HN001 treatment alters postpartum anxiety, cortical monoamines, and the gut microbiome
- 19 March 2024
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 165, 107033
Maternal probiotic Lactocaseibacillus rhamnosus HN001 treatment alters postpartum anxiety, cortical monoamines, and the gut microbiome
- 14 July 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (7) , e13321
The 7th International Meeting on the Neuroscience of Parenting
- 14 July 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (7) , e13321
The 7th International Meeting on the Neuroscience of Parenting
- Open Access
- 2 May 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (7) , e13261
Gestational stress and perinatal SSRIs differentially impact the maternal and neonatal microbiome‐gut‐brain axis
Selective serotonin reuptake inhibitors (SSRIs) are the most popular antidepressant medications used to manage perinatal mood disturbances, yet our understanding of how they affect the microbiome‐gut‐brain axis of the mother and offspring is limited. The purpose of this study was to determine how peripartum SSRI treatment may prevent the effects of gestational stress on plasticity in the maternal hippocampus, plasticity in the neonatal brain and related changes in gut microbiota. To do this Sprague–Dawley female rats were left untreated or subjected to unpredictable stress during pregnancy. Half of the females were supplemented daily with fluoxetine. On postpartum day 2 brains were collected for measurement of plasticity (neurogenesis and microglia content) in the maternal hippocampus and in the neonatal brain. Glucocorticoid receptor density was also investigated in the maternal hippocampus. Microbiota composition was analyzed in fecal samples of dams during and after pregnancy, and colon tissue samples from offspring on postnatal day 2. Main findings show there are significant changes to the maternal microbiome‐gut‐brain axis that may be fundamental to mediating plasticity in the maternal hippocampus. In addition, there is significant impact of gestational stress on neonatal gut microbiota and brain microglia density, while the effects of SSRIs are limited. This is the first study to explore the impact of gestational stress and SSRIs on the microbiome‐gut‐brain axis in the mother and neonate. Findings from this study will help inform pathways to intervention strategies including stress reduction techniques and/or microbiota targeted nutritional approaches directed towards improving maternal gut health and outcomes for mother and neonate.
- 2 May 2023
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 35 (7) , e13261
Open AccessGestational stress and perinatal SSRIs differentially impact the maternal and neonatal microbiome‐gut‐brain axis
Selective serotonin reuptake inhibitors (SSRIs) are the most popular antidepressant medications used to manage perinatal mood disturbances, yet our understanding of how they affect the microbiome‐gut‐brain axis of the mother and offspring is limited. The purpose of this study was to determine how peripartum SSRI treatment may prevent the effects of gestational stress on plasticity in the maternal hippocampus, plasticity in the neonatal brain and related changes in gut microbiota. To do this Sprague–Dawley female rats were left untreated or subjected to unpredictable stress during pregnancy. Half of the females were supplemented daily with fluoxetine. On postpartum day 2 brains were collected for measurement of plasticity (neurogenesis and microglia content) in the maternal hippocampus and in the neonatal brain. Glucocorticoid receptor density was also investigated in the maternal hippocampus. Microbiota composition was analyzed in fecal samples of dams during and after pregnancy, and colon tissue samples from offspring on postnatal day 2. Main findings show there are significant changes to the maternal microbiome‐gut‐brain axis that may be fundamental to mediating plasticity in the maternal hippocampus. In addition, there is significant impact of gestational stress on neonatal gut microbiota and brain microglia density, while the effects of SSRIs are limited. This is the first study to explore the impact of gestational stress and SSRIs on the microbiome‐gut‐brain axis in the mother and neonate. Findings from this study will help inform pathways to intervention strategies including stress reduction techniques and/or microbiota targeted nutritional approaches directed towards improving maternal gut health and outcomes for mother and neonate.